HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lohnes, D. Articles by Jones, G. Search for Related Content PubMed PubMed Citation Articles by Lohnes, D. Articles by Jones, G. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 262, Issue 30, 14394-14401, 10, 1987

Side chain metabolism of vitamin D3 in osteosarcoma cell line UMR-106. Characterization of products

D Lohnes and G Jones
Department of Biochemistry, Queen's University, Kingston, Ontario, Canada.

Previous work has shown that 25-hydroxyvitamin D3 (25-OH-D3) and 1 alpha, 25-dihydroxyvitamin D3 (1,25-(OH)2D3) may be metabolized in the mammalian kidney through a side chain oxidation pathway resulting in C23-C24 cleavage, yielding 24,25,26,27-tetranor-23-OH-D3. In the present study, we have used UMR-106 clonal osteoblast cells to demonstrate that products of the side chain oxidation pathway are produced by an osteoblast-like cell. Cells cultured on microcarrier beads and incubated in the presence of pharmacological levels of substrate (1.4 microM, either 25-OH-D3 or 1,25-(OH)2D3) produced sufficient quantities of metabolite to allow identification through mass spectrometry. In addition, putative metabolites were identified through comigration with authentic standards on three high pressure liquid chromatography systems, chemical modification by NaBH4 and periodate, and UV spectral characterization. The pathway was undetectable unless the cells had been exposed to 1,25-(OH)2D3 prior to incubation with substrate. We have shown that 1,25-(OH)2D3 induces the 24-hydroxylase and perhaps also the other enzymes of this pathway in the bone cell. Although we used pharmacological concentrations of substrate to demonstrate the existence of the side chain oxidation pathway in bone cells, physiological levels of 25-OH-D3 or 1,25-(OH)2D3 were also metabolized through the pathway, at least as far as the penultimate product. We speculate that the side chain oxidation pathway may be ubiquitous among vitamin D target tissues.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Masuda, V. Byford, A. Arabian, Y. Sakai, M. B. Demay, R. St-Arnaud, and G. Jones Altered Pharmacokinetics of 1{alpha},25-Dihydroxyvitamin D3 and 25-Hydroxyvitamin D3 in the Blood and Tissues of the 25-Hydroxyvitamin D-24-Hydroxylase (Cyp24a1) Null Mouse Endocrinology, February 1, 2005; 146(2): 825 - 834. [Abstract] [Full Text] [PDF]

				M. Kamao, S. Tatematsu, S. Hatakeyama, T. Sakaki, N. Sawada, K. Inouye, K. Ozono, N. Kubodera, G. S. Reddy, and T. Okano C-3 Epimerization of Vitamin D3 Metabolites and Further Metabolism of C-3 Epimers: 25-HYDROXYVITAMIN D3 IS METABOLIZED TO 3-EPI-25-HYDROXYVITAMIN D3 AND SUBSEQUENTLY METABOLIZED THROUGH C-1{alpha} OR C-24 HYDROXYLATION J. Biol. Chem., April 16, 2004; 279(16): 15897 - 15907. [Abstract] [Full Text] [PDF]

				G. JONES, S. A. STRUGNELL, and H. F. DeLUCA Current Understanding of the Molecular Actions of Vitamin D Physiol Rev, October 1, 1998; 78(4): 1193 - 1231. [Abstract] [Full Text] [PDF]

				S. Masuda, V. Byford, R. Kremer, H. L. J. Makin, N. Kubodera, Y. Nishii, A. Okazaki, T. Okano, T. Kobayashi, and G. Jones In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines J. Biol. Chem., April 12, 1996; 271(15): 8700 - 8708. [Abstract] [Full Text] [PDF]